Target expression profiling

Target expression profiling

A key step towards target evaluation

Early stage development of a new therapeutic antibody requires a target expression profile. Targets that are expressed on tumour cells, for example, should ideally have as little expression as possible in healthy tissue to minimize undesirable effects. Expression analysis is also essential to assist on animal model choice for downstream validation steps, or to select the most relevant indication.

In collaboration with the histology platforms at the IPC (Institut Paoli-Calmettes) and the CRCM (Centre de Recherche en Cancérologie de Marseille), MI-mAbs determines the expression and localisation of new therapeutic targets by immunohistochemistry (IHC) and immunofluorescence (IF).



Using a Ventana Discovery XT® instrument for easy automation and increased reproducibility and productivity, analyses can be performed on tissues of different nature and origin:

  • Murine or human (patient samples are obtained through the Institut Paoli-Calmettes)

  • Healthy or pathological

  • Frozen or paraffin-embedded

Among its expression profiling team, MI-mAbs counts with an IHC expert engineer, as well as an experienced anatomopathologist (MD) for analysis of the stained sections.

  • Frozen and paraffin-embedded sample preparation and sectioning

  • Histology:

    • Classical dyes: HES (Hematoxyline Eosine Safran) and May-Grünwald-Giemsa (MGG) for tissue and cell morphology

    • Special dyes:  Trichrome de Masson, PAS, Bleu Alcian, etc.

  • Immunohistochemistry:

    • Immunostaining validation on frozen or FFPE tissues

    • IHC and IF multiplexing

  • Tissue microarrays of paraffin blocks: biomarker screening, simultaneous characterization of multiple samples

  • Slide scanning to obtain virtual slides for image analysis

  • Histopathology analysis

In addition to target validation and expression profiling, IHC analysis can be used at several other steps throughout the development of a therapeutic antibody:

  • Antibody specificity validation in tissues

  • Guide dose selection for downstream applications

  • Biomarker development if an antibody is intended for diagnostic purposes

  • Tissue organization in response to an antibody treatment (see In vivo immunopharmacology)